Corcept Therapeutics Inc
NASDAQ:CORT
Corcept Therapeutics Inc
Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs.
The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.
Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs.
The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.
Revenue Beat: 2025 revenue reached $761 million, up from $675 million in 2024, surpassing prior expectations.
Strong Growth Outlook: 2026 revenue guidance was set at $900 million to $1 billion, mainly from the Cushing's syndrome franchise.
Net Income Decline: Net income dropped to $99.7 million from $141.2 million in the previous year.
Cash Position: The company ended 2025 with $532 million in cash and investments, after executing $245 million in stock repurchases.
Pharmacy Transition: The switch to a new specialty pharmacy disrupted supply late in 2025 but is now complete, with capacity and new prescription volumes rebounding strongly.
Relacorilant Setbacks: The FDA declined to approve relacorilant for Cushing's syndrome, despite positive trial data; the company will meet with the FDA in April to discuss next steps.
Oncology Progress: The Phase III ROSELLA trial showed a 35% reduction in risk of death in ovarian cancer, with full results to be presented soon and an FDA decision expected by July 11.
Pipeline Momentum: Key studies in diabetes (CATALYST), hypertension (MOMENTUM), MASH, and ALS are advancing, with multiple data readouts expected over the coming year.
